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Edited by Masayuki MiyasakaAbstract Expression of the telomerase catalytic subunit
(TERT) is the rate-limiting determinant of telomerase activity
in most human cells. In this work, we examined the participation
of protein kinase C (PKC) in the regulation of hTERT expres-
sion in human T lymphocytes. Transient expression assays using
luciferase reporter plasmids containing hTERT promoter showed
that overexpression of PKC h, but not the other PKC isoforms,
could activate the promoter activity of hTERT in resting T lym-
phocytes. Among the PKC h-activated signalings, we presented
evidence that the expression of hTERT is mediated through
NFjB but not through MEK or c-Jun N-terminal kinase path-
ways. Analysis of the hTERT promoter occupancy in vivo using
chromatin immunoprecipitation assays, however, did not detect
an increased binding of NFjB to the hTERT promoter in the
activated T cells, although an increased binding of cMyc and
Sp1 was detected. Together with the observation that inhibition
of NFjB eliminated the induction of cMyc in activated T cells,
these results suggest that PKC h-activated NFjB signaling reg-
ulates the expression of hTERT via cMyc in human T lympho-
cytes.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Human telomerase is a ribonucleoprotein complex composed
of an RNA component (hTER), a reverse transcriptase protein
subunit (hTERT) and several associated proteins [1]. Telome-
rase directs the synthesis of telomeric repeats at chromosome
ends and is known to play a key role in maintaining telomere
length and in replicative senescence [2]. It has been widely ac-
cepted that telomerase activation is crucial for transformed
cells to stabilize their telomere length and to acquire inﬁnite
replicative potentials during oncogenic process, whereas most
normal somatic cells undergo telomeric attrition and replicative
senescence because telomerase is stringently repressed [3,4].
However, substantial levels of telomerase activity are seen in
some normal tissues, such as male germ cells, activated lympho-
cytes and in certain types of stem cell populations [5,6]. The reg-
ulated expression of telomerase in highly proliferating normal*Corresponding author. Fax: +886 3 211 8700.
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[7,8]. So far, such tightly proliferation-regulated telomerase
expression in normal cells has been poorly understood.
The regulation of telomerase activity is known to occur at
various levels, including transcription, mRNA splicing, matu-
ration and modiﬁcation of hTER and hTERT, transport and
subcellular localization of each component, and assembly of
active telomerase [1]. Among the several components of
human telomerase, only the catalytic component hTERT
seems to be the rate-limiting determinant of telomerase activ-
ity. For examples, studies on the correlation between telome-
rase activity and the expression of hTER, hTEP1, and
hTERT have indicated that telomerase activity is strongly cor-
related with the abundance of hTERT mRNA [9,10], but not
the abundance of mRNA for hTEP1 and hTER [11–13]. Sim-
ilarly, ectopic expression of hTERT in several somatic cells has
been shown to be suﬃcient to restore telomerase activity [14–
17], indicating that hTERT is the key regulator of enzyme
activity. Expression of hTERT in human cells is regulated pri-
marily at the level of transcription [1]. Sequence analysis has
revealed that the hTERT promoter contains hormone response
elements and binding sites for several transcription factors
including cMyc, Spl, NFjB and others [18–20], implicating
that hTERT expression may be regulated by multiple factors.
Several activators (cMyc, Spl) and repressors (WTI, Mad1,
E2FI, p53, Menin, MZF-2, etc.) for hTERT expression have
been identiﬁed [1,21–23]. Exactly how these activators and
repressors function in the diﬀerent types of cells to regulate
the expression of hTERT remains largely unknown.
T lymphocytes, a key player in adaptive immunity, require
extensive cell division and clonal expansion for their functions.
To achieve this, T lymphocytes may develop regulatory mecha-
nism to overcome the problem of replicative senescence. It has
been reported that the expression of telomerase activity is strin-
gently regulated during T lymphocyte development and diﬀer-
entiation [6]. Telomerase activity is low or undetectable in
peripheral T lymphocytes, but is upregulated several hundred-
fold upon activation [6,24]. Activation of T cells through T cell
receptor is known to mediate through complex signaling path-
ways including the activation of protein kinase C (PKC)-depen-
dent signaling pathways [25–27]. Indeed, the expression of
telomerase activity in T lymphocytes has been shown to require
PKC-dependent activities [28–30]. As yet, the molecular details
for the participation of PKC-dependent signaling in the activa-
tion of telomerase remain largely unknown. In this work, the
speciﬁc PKC isoform involved and the components of PKC-
dependent signaling were investigated for their participation
in the induction of hTERT expression in T lymphocytes.blished by Elsevier B.V. All rights reserved.
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2.1. Chemicals, enzymes, antibodies, and oligonucleotides
RPMI medium 1640, Hanks’ balanced salt solution (HBSS), Super-
script II reverse transcriptase, TRIzol reagent, antibiotics, and phyto-
hemagglutinin (PHA) were purchased from Sigma Co., RNase
inhibitor, MAP kinase kinase (MEK) inhibitors 2 0-amino-3 0-meth-
oxyﬂavone (PD98059) and bis[amino[(2-aminophenyl)thio]methylene]
butanedinitrile (U0126), c-Jun N-terminal kinase (JNK) inhibitor
anthra[1,9-cd]pyrazol-6(2H)-one (SP600125), and NFjB inhibitors
helenalin and carbobenzoxy-L-leucyl-L-leucyl-L-leucinal (MG132)
were purchased from CalBiochem Co., Taq DNA polymerase was
from Viogene Co., Taipei, Taiwan. The sequence and source of TS,
CX, LT5 and LT6 oligonucleotides were previously described [31].
The oligonucleotides WW144 (5 0-TGG TAT CGT GGA AGG ACT
CAT GAC-30), WW145 (5 0-ATG CCA GTG AGC TTC CCG TTC
AGC-3 0), cMyc-F (5 0-AGAGTCTGGATCACCTTCTGCTGG-3 0)
and cMyc-R (5 0-ACGGACAGGATGTATGCTGTGG-3 0) were ob-
tained from Protech Co., Taipei, Taiwan. Gel electrophoresis reagents
were from Bio-Rad. Antibodies against NFjB p50, cMyc and Sp1
were purchased from Upstate, NY. Anti-human CD3 and anti-human
CD28 were obtained from BioLegend. Antibodies against PKC a, b1,
d, f, and h were from Santa Cruz Biotech. All other chemicals were
from Sigma Co.
2.2. Plasmids
Plasmids that overexpress wild-type (WT) or constitutively active
(CA) mutant form of PKC a, b1, d, f [32], and h [33] were kindly sup-
plied by Drs. P. Parker and S. Shaw, respectively. The luciferase repor-
ter plasmid pBTdel-408 [18] that contains the core promoter of hTERT
was kindly supplied by Dr. I. Horikawa. The pSV-b-galactosidase
plasmid was kindly provided by Dr. Y.S. Chang. The pGL3-basic
and pGL3-control plasmids were obtained from Promega.
2.3. Cell culture
The peripheral blood mononuclear cells (PBMC) and lymphocytes
(PBL) were isolated and cultured as previously described [30]. Naso-
pharyngeal carcinoma-derived cell line NPC-076 was cultured in
DMEM as previously described [31].
2.4. Telomerase activity assay
A PCR-based telomeric repeat ampliﬁcation protocol (TRAP) [34]
was used for assaying telomerase activity. The preparation of cell
extracts, the condition for PCR ampliﬁcation and analysis of PCR
products by electrophoresis on polyacrylamide gel were as described
[30].
2.5. RT-PCR analysis
Total RNA was extracted by TRIzol isolation reagent following
manufacturer’s instruction. The primers used were: LT5 and LT6 for
hTERT, cMyc-F and cMyc-R for cMyc, and WW144 and WW145
for GAPDH. The conditions for RT-PCR analysis were as described
[30].
2.6. DNA transfection and reporter gene assay
The protocol for DNA transfection of unstimulated human T cells
followed that suggested by Amaxa Biosystems. In brief, 5 · 106 freshly
prepared PBMC were suspended in 0.1 ml of Human T Cell Nucleofec-
tor Solution (Amaxa Biosystems), mixed with 5 lg PKC-expressing
plasmid DNA, 5 lg luciferase-reporter DNA and 1 lg pSV-b-galacto-
sidase DNA, and transferred into an Amaxa certiﬁed cuvette. After
inserting the cuvette into the cuvette holder of Nucleofector, the cells
were electroporated using program U-14. Electroporated T cells were
quickly placed in RPMI 1640 medium containing 10% FBS, and cul-
tured for 24 h. The cells were harvested and lysed in 50 ll of lysis buﬀer
(Promega). Samples containing 50-lg protein were used to measure the
luciferase activity in an illuminometer (Berthold autolumate model
LB953). The b-galactosidase activity per transfection, determined with
a spectrophotometer at OD420, was used as the internal control. The
pGL3-basic and pGL3-control plasmids were served as the negative
and positive controls, respectively. Transfection of plasmid DNA into
NPC-076 cells using LipofectAMINE 2000 followed the supplier’s
instructions.2.7. Chromatin immunoprecipitation (ChIP) assay
The treated PBL was suspended in RPMI 1640 medium containing
1% formaldehyde (106 cells/ml), and incubated at 37 C for 10 min.
The crosslinking reaction was stopped by adding glycine to a ﬁnal con-
centration of 0.125 M and the cells were collected by centrifugation.
After washing twice with cold PBS containing 10 lM PMSF and pro-
tease inhibitor cocktail (Sigma), the cell pellets were stored at 70 C.
The preparation of cell lysates, condition for the sonication of DNA,
and the isolation of antibody-bound chromatin followed that as de-
scribed [35]. The sets of primers used for the detection of antibody-
bound chromatin DNA in the hTERT promoter region include: (i) Re-
gion 0 (+47 to +356). F0: 5 0-GCCACTACCGCGAGGTGCT-30; R0:
5 0-CACTCGGGCCACCAGCTCC-3 0, (ii) Region 1 (22 to 296).
F1: 5 0-TGCCCCTTCACCTTCCAG-3 0; R1: 5 0-CAGCGCTGCC-
TGAAACTC-3 0, (iii) Region 2 (274 to 484). F2: 5 0-ACA-
TCATGGCCCCTCCCT-30; R2: 5 0-CTGGAAGGTGAAGGGGCA-
3 0, and (iv) Region 3 (590 to 793). F3: 5 0-GATTAACAGAT-
TTGGGGT-3 0; R3: 5 0-AGGACGGGAGGCGCGTAGA-30.2.8. Western blot
Western blot analysis was performed as previously described [31].3. Results and discussion
Expression of telomerase in activated T cells is known to re-
quire PKC-dependent induction of hTERT expression [28,30].
To determine the role of individual PKC isoform in the induc-
tion of hTERT, we employed a luciferase reporter to examine
the eﬀects of PKC overexpression on the promoter activity of
hTERT in unstimulated T cells. Plasmid that overexpresses
wild-type (WT) or constitutively-active mutant form (CA) of
PKC, and a luciferase reporter plasmid were co-transfected
into unstimulated T cells and the activation of hTERT pro-
moter activity was analyzed after 24 h of culturing. As shown
in Fig. 1A, overexpression of wild-type or constitutively-active
mutant form of PKC a, b1, d, and f did not activate hTERT
promoter activity. In contrast, overexpression of PKC h acti-
vated the hTERT promoter activity about 2–6 fold. Surpris-
ingly, overexpression of wild-type PKC h produced an even
greater activation of the hTERT promoter than that produced
by the CA-mutant. Analyses of PKC by Western blot, how-
ever, failed to detect any signiﬁcant increase of PKC level in
the T cells transfected with PKC plasmids (unpublished data).
Presumably, the low transfection eﬃciency of the primary T
cells masks the detection of ectopically expressed PKC over
that of the endogenous ones. To remedy this technical prob-
lem, we examined the expression of PKC plasmids in a highly
transfectable cells, NPC-076. As shown in Fig. 1B, the levels of
PKC a, h, and f, but not b1 or d, were greatly increased in the
cells transfected with PKC plasmids. Assuming that the levels
of expression/stability are similar both in the transfected NPC-
076 and T cells, these results indicate that only the overexpres-
sion of PKC h could transactivate the hTERT expression.
Although the underlying mechanism for the greater transacti-
vation activity of the wild-type PKC h is not known, it cannot
be accounted simply by the higher levels of PKC expressed by
the wild-type plasmid, since similar levels of ectopically ex-
pressed PKC were detected in the NPC-076 cells transfected
with wild-type or mutant PKC h plasmids.
Since PKC h is known to play a central role in the signaling
of T cell activation [25,26], we addressed which one of the
PKC h-dependent signaling pathways is involved in the induc-
tion of hTERT and telomerase expression. Although the



























Fig. 1. Activation of the hTERT promoter by overexpression of individual PKC isoform. (A) Unstimulated T lymphocytes were co-transfected with
a PKC-expressing plasmid and a luciferase reporter plasmid pBTdel-408, and assayed for luciferase activity as described in ‘‘Section 2’’. pGL3
control and pGL3 basic served as the positive and negative controls, respectively. Vector served as the control for comparison with the PKC-
expressing plasmid. Values shown represent the results from two independent experiments with the indicated error bars. (B) NPC-076 cells were
transfected with PKC plasmids and the expression of PKC isoform was monitored after 24 h by Western blot as described in ‘‘Section 2’’. The
plasmids V, WT, and CA indicate the vector control, the wild-type PKC and the constitutively-active mutant PKC, respectively.
Fig. 2. Eﬀect of PD98059 and SP600125 on the expression of hTERT and telomerase activity in PHA-treated PBL. PBL were treated with PHA in
the presence or absence of 50 lM PD98059 (panel A), or 12.5 lM SP600125 (panel B) for the indicated times, and assayed for the expression of
telomerase activity (top) and hTERT (bottom) as described in ‘‘Section 2’’. Lane P is a positive control using cell extract or RNA obtained from
telomerase-positive HL-60 cells. Lane N is a negative control with no cell extract or RNA. The expression of GAPDH was included as a loading
control in the RT-PCR analysis. Results shown are from one of three similar experiments.
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and NFjB pathways has been shown to account for a number
of major events observed in T cell activation [25–27]. Here, we
employed inhibitors speciﬁc for MEK, JNK and NFjB to
investigate the role of these pathways in the expression of
hTERT and telomerase activity in activated T cells. As shown
in Fig. 2A, the induction of hTERT expression and telomerase
activity was essentially not aﬀected by the presence of MEK
inhibitor PD98059 in the phytohemagglutinin (PHA)-stimu-
lated T cells. Similar results were also obtained with another
MEK inhibitor U0126 (data not shown). Inhibition of JNK
by SP600125 also did not inhibit the expression of hTERT
and telomerase activity in the PHA-stimulated T cells
(Fig. 2B), indicating that MEK and JNK are not involved in
the induction of hTERT expression. In contrast, a complete
inhibition of hTERT induction and telomerase activation
was observed when the NFjB inhibitors MG132 or helenalin
were added simultaneously with PHA (Fig. 3). A similar pat-
tern of hTERT inhibition was also observed in the T cells acti-
vated by anti-CD3/CD28 (data not shown), indicating that the
signaling through NFjB plays an important role in the expres-
sion of hTERT in the T cells activated with PHA or anti-CD3/
CD28.
Our observation for a major role of NFjB in the transcrip-
tional control of hTERT expression suggests that NFjB acti-
vates the hTERT promoter either directly or indirectly. Since
putativeNFjBbinding sites are present in the hTERTpromoter
and a direct binding of NFjB to themouse TERT promoter has
been demonstrated [36], we investigated if the activation of
hTERT expression may be mediated by a direct binding of
NFjB to the hTERT promoter. We have employed chromatinFig. 3. Eﬀect of NFjB inhibitors on the expression of hTERT and telomer
presence or absence of 0.5 lMMG132 (panel A) or 1 lM helenalin (panel B),
(bottom) as described in ‘‘Section 2’’. Lane P is a positive control using cell ex
a negative control with no cell extract or RNA. Results shown are from onimmunoprecipitation assay to examine the hTERT promoter
occupancy in vivo, and the results are shown in Fig. 4. NFjB-
bindingwas detected in theRegions 0 and 1 of hTERTpromoter
in unstimulated lymphocytes but not in the activated cells. A
weak NFjB-binding to Region 3 was detected in both unstimu-
lated and activated T cells. Since the expression of hTERT is not
detected in unstimulated T cells, the observed NFjB-binding in
Regions 0 and 1 may in fact play a negative regulatory function
for hTERT expression. The lack of increased NFjB-binding to
the hTERT promoter in the activated T cells suggests that a di-
rect NFjB-binding is unlikely to account for the transactivation
of hTERT expression. Contrary to that observed for NFjB, an
increased binding of cMyc and Sp1 to the hTERTpromoter was
detected in the PHA-treated cells (Fig. 4).
A major role of NFjB in the transcriptional regulation of
hTERT has also been reported in HTLV-I-transformed T cells
[37] and in estrogen-treated ovarian cancer cells [38]. In the
case of estrogen-treated ovarian cancer cells, a PI3K/Akt/
NFjB cascade is thought to regulate both the transcriptional
expression and post-transcriptional phosphorylation of
hTERT, although the molecular mechanism by which NFjB
regulates the transcription of hTERT was not known. In the
case of HTLV-I-transformed T cells, an increased binding of
c-Myc and Sp1 but not NFjB is suggested to be involved
in the NFjB-mediated activation of the hTERT promoter.
Similar to the ﬁnding of Sinha-Datta et al. [37], our data of
the hTERT promoter occupancy in vivo have revealed an
increased binding of c-Myc and Sp1, but not NFjB, to the
hTERT promoter in the activated T cells (Fig. 4), suggesting
that NFjB-mediated activation of the hTERT may act via
increased binding of c-Myc and Sp1.ase activity in PHA-treated PBL. PBL were treated with PHA in the
and assayed for the expression of telomerase activity (top) and hTERT
tract or RNA obtained from telomerase-positive HL-60 cells. Lane N is
e of three similar experiments.
Fig. 4. hTERT promoter occupancy in vivo by chromatin immunoprecipitation assay (ChIP). (A) Schematic presentation of the hTERT promoter
and the primer locations for Regions 0, 1, 2, and 3. The sites marked with star (*) are putative binding sites for Sp1 and NFjB. (B) hTERT promoter
occupancy in vivo. PBL were treated with PHA for the indicated times and the chromatin bound by transcriptional factors Sp1, cMyc, and NFjB
were analyzed by ChIP assay as described in ‘‘Section 2’’. The PCR products from 2.5% input samples and from DNA precipitated in the absence of
antibody (No antibody) were included for comparison. Results shown are from one of two similar experiments.
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vate hTERT promoter [39–41] and cMyc is known to be po-
tently transactivated by NFjB [42], it raises the possibility
that NFjB may activate the expression of cMyc which in turn
transactivates the expression of hTERT. To test this postulate,
we examined the eﬀect of NFjB inhibitors on the expression of
cMyc in activated T cells. As shown in Fig. 5, inhibition of
NFjB completely abolished the induction of cMyc expression
in the activated T cells, suggesting that the NFjB-mediated
expression of cMyc is critical for the expression of hTERT
in the activated T cells.Fig. 5. Eﬀect of NFjB inhibitors on the expression of cMyc in PHA-
treated PBL. PBL were treated with PHA in the presence or absence of
0.5 lMMG132 (panel A) or 1 lM helenalin (panel B), and assayed for
the expression of cMyc by RT-PCR as described in ‘‘Section 2’’. The
expression of GAPDH served as a loading control. Results shown are
from one of two similar experiments.Taken together, these results establish that PKC h is the
PKC isoform that is involved in the transcriptional regulation
of hTERT expression in T lymphocytes. Of the several PKC h-
mediated signaling pathways, we provide evidence that the
expression of hTERT is mediated through NFjB but not
through MEK or JNK pathways (Figs. 2 and 3). Although
the mechanism by which NFjB mediates the activation of
hTERT expression is not fully deduced at present, our results
suggest that NFjB does not participate in the direct transacti-
vation of hTERT promoter, but may potently activate cMyc
expression which in turn transactivates the expression of
hTERT in the activated T cells.
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